A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis

Summary

This is a single-dose, double-blind, placebo-controlled, parallel group safety, tolerability and pharmacodynamic study of subcutaneously (SC) administered REGN88 in rheumatoid arthritis patients who are receiving concomitant methotrexate. Four (4) parallel groups of 8 subjects each with active rheumatoid arthritis will be dosed SC.

Timeline

Start

2008-09

Primary completion

2009-03

Completion

2009-05

Drugs

Indications